CARA - Cara Therapeutics, Inc.
| Previous Close | 16.80 |
| Open | 16.88 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 1100 |
| Day's Range | 16.56 - 17.21 |
| 52 Week Range | 11.11 - 28.50 |
| Volume | 639,736 |
| Avg. Volume | 1,053,214 |
| Market Cap | 553.609M |
| Beta | 3.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.62 |
| Earnings Date | Aug 3, 2017 - Aug 7, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.00 |
Yahoo Finance Video•25 days agoNYSE trader: Cannabis stocks are migrating from Canada to the US—a trend here to stay
Keith Bliss of Cuttone and Company joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss Canopy Growth Corp (CGC), which begins trading on NYSE today and is the first pure cannabis play to achieve a listing on the exchange.
Yahoo Finance Video•2 months ago4/20: Marijuana, hemp legalization moves ahead in many states
Senate Democratic leader Chuck Schumer says he’s introducing a bill to decriminalize marijuana at the federal level. Yahoo Finance’s Alexis Christoforous and Dan Ahrens, Managing Director & COO at AdvisorShares, discuss marijuana and hemp sales.
- Motley Fool•4 days ago
Here's Why Cara Therapeutics Jumped 26.3% in May
The biotech signed a big partnership to cap off the month.
- Motley Fool•9 days ago
Better Marijuana Stock: GW Pharmaceuticals vs. Cara Therapeutics
Which stock wins in a one-on-one battle between two biotechs with cannabinoid pipeline candidates?
- Motley Fool•11 days ago
Where Will Cara Therapeutics, Inc. Be in 5 Years?
Cara Therapeutics is nearing an inflection point that could make it or break it over the next five years.
- Zacks•20 days ago
Biotech Stock Roundup: GILD Epclusa's China Approval, BMRN Palynziq's FDA Nod
The biotech sector grabbed headlines last week with drug approvals and licensing deals. Investors will await pipeline development news at the ASCO in the coming week.
- GlobeNewswire•20 days ago
Cara Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference
STAMFORD, Conn., May 29, 2018-- Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively ...
- Motley Fool•24 days ago
Why Cara Therapeutics Shares Jumped 10% Today
Investor optimism continues following an important licensing deal earlier in the week.
- Motley Fool•25 days ago
Does This New Partnership Make Cara Therapeutics Stock a Buy Now?
A new deal with a major dialysis provider could propel Korsuva much further than expected.
- ACCESSWIRE•26 days ago
Today’s Research Reports on Stocks to Watch: Avinger and Cara Therapeutics
NEW YORK, NY / ACCESSWIRE / May 24, 2018 / Avinger, Inc. and Cara Therapeutics were both exploding in Wednesday trading on positive news. Avinger shares blasted off after the company announced it had gained ...
- Motley Fool•26 days ago
Why Wall Street Analysts Think This Biotech Stock Could Nearly Double
Cara Therapeutics hopes to still succeed with a drug that's failed once already.
- Benzinga•27 days ago
Cara Therapeutics Shares Jump On Licensing Deal For Pruritis Treatment
Cara said it has licensed worldwide rights — except in the U.S., Japan and South Korea — to commercialize Korsuva injection with VFMCRP, a joint venture between Vifor Pharma and Fresenius Medical Care AG & Co. (ADR) (NYSE: FMS). The deal provides for a $50-million upfront cash payment to Cara and an equity investment of $20 million via share sales at $17 apiece.
- Benzinga•27 days ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Tiffany & Co. (NYSE: TIF ) stock was trading higher ...
- Simply Wall St.•27 days ago
Investors Are Undervaluing Cara Therapeutics Inc (NASDAQ:CARA) By 26%
Today I will be providing a simple run-through of the discounted cash flows (DCF) method to estimate the attractiveness of Cara Therapeutics Inc (NASDAQ:CARA) as an investment opportunity. If youRead More...
- Motley Fool•27 days ago
Why Cara Therapeutics' Stock Is Popping Today
The biotech signed a favorable licensing deal for its lead product candidate, sending its shares higher.
- GlobeNewswire•27 days ago
Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Enter into Ex-U.S. Licensing Agreement to Commercialize KORSUVA™ Injection in Dialysis Patients with Pruritus
Cara Therapeutics, Inc. (CARA), a U.S. biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced that it has licensed worldwide rights, except in the U.S., Japan and South Korea, to commercialize KORSUVA (CR845/difelikefalin) injection for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in dialysis patients to Vifor Fresenius Medical Care Renal Pharma Ltd (VFMCRP), a joint company of Vifor Pharma Group (VIFN.VX) and Fresenius Medical Care (FMS) that specializes in treatments for CKD. The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to KORSUVA injection for this indication, for which there are currently no approved therapies in the U.S. or E.U.
- Thomson Reuters StreetEvents•last month
Edited Transcript of CARA earnings conference call or presentation 9-May-18 8:30pm GMT
Q1 2018 Cara Therapeutics Inc Earnings Call
- Motley Fool•last month
Forget Cara Therapeutics' Earnings -- Here's the Real News
This little biotech could win by playing small ball.
- GlobeNewswire•last month
Cara Therapeutics to Present at the International Investigative Dermatology 2018 Meeting
STAMFORD, Conn., May 14, 2018-- Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively ...
- Benzinga•last month
Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 9) ABIOMED, Inc. (NASDAQ: ABMD ) Adaptimmune Therapeutics PLC – ...
- Associated Press•last month
Cara: 1Q Earnings Snapshot
On a per-share basis, the Stamford, Connecticut-based company said it had a loss of 51 cents. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...
- GlobeNewswire•last month
Cara Therapeutics Reports First Quarter 2018 Financial Results
STAMFORD, Conn., May 09, 2018-- Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively ...
- GlobeNewswire•2 months ago
Cara Therapeutics to Announce First Quarter 2018 Financial Results on May 9, 2018
STAMFORD, Conn., May 02, 2018-- Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of CARA earnings conference call or presentation 4-May-17 8:30pm GMT
Q1 2017 Cara Therapeutics Inc Earnings Call
- GlobeNewswire•2 months ago
Research Report Identifies Cara Therapeutics, MGE Energy, IDEXX Laboratories, Sterling Construction, TTM Technologies, and Regis with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, April 30, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
